Veterinary Medicine Information website

Metrocare 500 mg tablets for dogs and cats

Authorised
  • Metronidazole
Download as PDF

Product identification

Medicine name:
Metrocare 500 mg tablets for dogs and cats
Active substance:
  • Metronidazole
Target species:
  • Dog
  • Cat
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Metronidazole
    500.00
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Tablet
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QJ01XD01
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Belgium
Available in:
  • Belgium
Package description:
  • 10 tablets - 1 PVC-Aluminium-Oriented polyamide -Aluminium blister pack in a cardboard box.
  • 90 tablets - 9 PVC-Aluminium-Oriented polyamide -Aluminium blisters pack in a cardboard box.
  • 250 tablets - 25 PVC-Aluminium-Oriented polyamide -Aluminium blisters pack in a cardboard box.
  • 30 tablets - 3 PVC-Aluminium-Oriented polyamide -Aluminium blisters pack in a cardboard box.
  • 100 tablets - 10 PVC-Aluminium-Oriented polyamide -Aluminium blisters pack in a cardboard box.
  • 20 tablets - 2 PVC-Aluminium-Oriented polyamide -Aluminium blisters pack in a cardboard box.
  • 70 tablets - 7 PVC-Aluminium-Oriented polyamide -Aluminium blisters pack in a cardboard box.
  • 80 tablets - 8 PVC-Aluminium-Oriented polyamide -Aluminium blisters pack in a cardboard box.
  • 40 tablets - 4 PVC-Aluminium-Oriented polyamide -Aluminium blisters pack in a cardboard box.
  • 60 tablets - 6 PVC-Aluminium-Oriented polyamide -Aluminium blisters pack in a cardboard box.
  • 50 tablets - 5 PVC-Aluminium-Oriented polyamide -Aluminium blisters pack in a cardboard box.
  • 500 tablets - 50 PVC-Aluminium-Oriented polyamide -Aluminium blisters pack in a cardboard box.

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Generic application (Article 13(1) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Ecuphar
Marketing authorisation date:
Manufacturing sites for batch release:
  • Lelypharma B.V.
Responsible authority:
  • Federal Agency For Medicines And Health Products
Authorisation number:
  • BE-V545413
Date of authorisation status change:
Reference member state:
  • Netherlands
Procedure number:
  • NL/V/0239/002
Concerned member states:
  • Austria
  • Belgium
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Hungary
  • Ireland
  • Luxembourg
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
French (PDF)
Published on: 13/03/2026
Download
German (PDF)
Published on: 13/03/2026
Download
Dutch (PDF)
Published on: 13/03/2026
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
French (PDF)
Published on: 13/03/2026
Download
German (PDF)
Published on: 13/03/2026
Download
Dutch (PDF)
Published on: 13/03/2026
Download

Labelling

This document does not exist in this language (English). You can find it in another language below.
French (PDF)
Published on: 17/08/2025
Download
German (PDF)
Published on: 17/08/2025
Download
Dutch (PDF)
Published on: 17/08/2025
Download

Combined File of all Documents

English (PDF)
Published on: 29/04/2025
Download